Skip to main content
OpenTrials
Completed

NCT Number: NCT07775911

RDW:MCHC as a Pragmatic Adjunct to SOFA Score in ICU Mortality Assessment

Critical illness represents a complex pathophysiological state characterized by systemic inflammation, oxidative stress, immune dysregulation, and progressive multiorgan dysfunction. In the Intensive Care Unit (ICU) setting, accurate and timely risk stratification remains paramount for optimizing patient outcomes, guiding therapeutic decision-making, and ensuring appropriate allocation of limited healthcare resources .Red cell distribution width (RDW), a quantitative measure of anisocytosis, has emerged as a powerful independent predictor of adverse outcomes across diverse clinical contexts, including sepsis, cardiovascular disease, and general ICU populations . Elevated RDW reflects dysregulated erythropoiesis and is mechanistically linked to chronic inflammation, oxidative stress, nutritional deficiencies, and impaired hematopoietic progenitor cell function .Mean corpuscular hemoglobin concentration (MCHC) represents the average hemoglobin concentration within erythrocytes and provides valuable information regarding red blood cell integrity, hemoglobin synthesis, and oxygen-carrying capacity. Reduced MCHC values are observed in conditions associated with impaired hemoglobin production, while elevated values may indicate hemolysis or red cell dehydration .Emerging evidence suggests that composite hematological ratios may enhance predictive performance compared to individual parameters by integrating complementary physiological information. The RDW:MCHC ratio is a novel biomarker that combines variability in red cell size with hemoglobin concentration, potentially offering a more comprehensive reflection of the underlying pathophysiological derangements characteristic of critical illness

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag university .faculty of medicine .internal medicine department

Sohag, Egypt

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • • ICU stay of at least 24 hours duration
  • Available complete blood count (CBC) parameters at the time
  • pregnant women at any gestational age and postpartum women (up to 6 weeks following delivery) are eligible
  • Adult patients (≥18 years)

Exclusion criteria

  • • Documented hematological malignancies (including leukemia, lymphoma, and myelodysplastic syndromes)
  • Recent blood transfusion (within 7 days prior to ICU admission)

Treatment and study plan

Primary outcomes

  1. 1. ICU Mortality

    Time frame: From ICU admission to ICU discharge or death, up to 90 days

    All-cause mortality during ICU stay, assessed through prospective follow-up from admission until discharge or death

Secondary outcomes

  1. ICU Length of Stay

    Time frame: From ICU admission to ICU discharge (assessed up to 90 days)

    Duration of intensive care unit admission measured in days from ICU admission until ICU discharge.

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Aug 20, 2026
Registry last updated
Aug 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.